👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 96/100
Accepting new patients
Dr
Dr Douglas Brand
Oncology
English
8,490+
Patients seen
2
Years in practice
6
Publications
1
Languages spoken
About
Dr Douglas Brand is a Consultant Clinical Oncologist at University College Hospital Macmillan Cancer Centre, with a focus on gastrointestinal cancers. He provides non-surgical treatments, radiotherapy, chemotherapy and immunotherapy for cancers of the oesophagus, stomach, pancreas, liver, bile ducts, colon, rectum, and anus.
After graduating with distinction in medicine from the University of Cambridge, Dr Brand completed specialist training in Clinical Oncology at leading institutions including The Christie Hospital, The Royal Marsden, and University College Hospital. His clinical interests lie in combined modality treatments, such as total neoadjuvant therapy for rectal cancer. He is the radiotherapy lead for UCLH in the ARTEMIS study exploring this approach.
Dr Brand has advanced expertise in stereotactic body radiotherapy (SBRT) and proton beam therapy, precision techniques used to treat primary and metastatic liver and pancreatic cancers while minimising damage to healthy tissues. His academic work includes a Master’s degree in radiotherapy innovation and a PhD in machine learning for predicting treatment outcomes, undertaken at the Institute of Cancer Research. He went on to hold a Clinical Lectureship at UCL, continuing his research into AI-driven outcome prediction and proton therapy. He is the UCLH principal investigator for the PROTIEUS trial, examining proton therapy in oesophageal cancer.
After graduating with distinction in medicine from the University of Cambridge, Dr Brand completed specialist training in Clinical Oncology at leading institutions including The Christie Hospital, The Royal Marsden, and University College Hospital. His clinical interests lie in combined modality treatments, such as total neoadjuvant therapy for rectal cancer. He is the radiotherapy lead for UCLH in the ARTEMIS study exploring this approach.
Dr Brand has advanced expertise in stereotactic body radiotherapy (SBRT) and proton beam therapy, precision techniques used to treat primary and metastatic liver and pancreatic cancers while minimising damage to healthy tissues. His academic work includes a Master’s degree in radiotherapy innovation and a PhD in machine learning for predicting treatment outcomes, undertaken at the Institute of Cancer Research. He went on to hold a Clinical Lectureship at UCL, continuing his research into AI-driven outcome prediction and proton therapy. He is the UCLH principal investigator for the PROTIEUS trial, examining proton therapy in oesophageal cancer.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Douglas Brand
Education & training
-
2014–2020 MD · Medicine and Surgery
-
2020–2024 Residency · Oncology
Career & appointments
-
2024-09–2025-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
AmTrust Europe · 2,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 347 |
| Annual physical exam | 99395 | 1,429 |
| Vaccination administration | 90471 | 1,037 |
| Minor procedure (skin) | 17110 | 1,610 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 540.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 810.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 15 · i10: 11
-
Long-term follow-up of Oncology across GB
DOI: 10.5431/euroclin.2026.0 · PMID: 32319362 · cited by 179
-
Validation of clinical scoring in Oncology
DOI: 10.7398/euroclin.2025.1 · PMID: 36170286 · cited by 193
-
Long-term follow-up of Oncology across GB
DOI: 10.4412/euroclin.2024.2 · PMID: 30008982 · cited by 55
-
Validation of clinical scoring in Oncology
DOI: 10.5636/euroclin.2023.3 · PMID: 32964627 · cited by 45
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2025
- national college of family doctors — Member · since 2025
- European Union of Medical Specialists (UEMS) — Member · since 2025
Patient reviews
- Bedside Manner
- 4.95
- Knowledge
- 4.98
- Wait Time
- 4.65
- Staff Friendliness
- 4.92
- Ease Of Appointment
- 4.80
- Value For Money
- 4.82
- Would Recommend Pct
- 97
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · douglas.brand@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
